| Management target | Revenue FY27 |
|---|
| Revenue growth | 23.1% YoY decline in Q1 FY27 |
|---|---|
| Margins | Gross margin at 71.5%; EBITDA margin at 2.2% |
| Order book | Sapala has meaningful order visibility for FY27 |
| Demand visibility | Healthy API order book; 140+ active CDMO projects |
| Management confidence | High for H2 recovery and long-term pipeline |
Growth
Revenue down 23.1% YoY. Pharma CDMO fell 38.7%; API+ fell 10.4%; Specialty Chemicals fell 34.7%.
Outlook
FY27 growth weighted towards H2. Investing INR 598 Mn capex; expanding Sapala stake for nucleic-acid business leadership.
Risks
Unfavorable product mix, negative operating leverage, and subsidiary consolidation (NJ Bio losses) pressured margins.
Last quarter's promises, checked
Delivered
- Guided Q1 FY27 to be low point → delivered INR 92 Mn EBITDA (= BEAT)
- Guided FY26 Gross Margin ~70.8% → delivered 71.5% in Q1 (= BEAT)
- Guided H1 FY27 to be weak → delivered 23.1% revenue decline (= BEAT)
Partly delivered
- Guided recovery from H2 FY27 → current results show 38.7% CDMO fall (= PARTIAL)
Missed
- Guided FY27 Capex INR 3,000 Mn → delivered INR 598 Mn in Q1 (= MISS)
Investor Presentation filed with NSE, NSE: COHANCE. Summary written with AI assistance from the document.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹459.25
- Market cap
- ₹17,571 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 165.4×Sector 50.4×
- Promoter holding
- 57.49%+0.00% QoQ
- FII holding
- 6.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences Merger & Restructuring Worth ₹95 Cr
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
- Value
- ₹95.00 Cr
Cohance Lifesciences Annual General Meeting
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.
Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.
Cohance Lifesciences Acquisition Worth ₹169.2 Cr
Cohance Lifesciences announced a $18 million investment across two subsidiaries, NJ Bio and Aruka Bio, to strengthen its ADC strategy and commercial integration.
- Value
- ₹169.2 Cr
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Cohance reported its lowest-ever quarter, plagued by customer shipment phasing and biotech funding delays, resulting in a 23% revenue decline. Management frames this as a trough, banking on H2 recovery through restocked commercial molecules.